Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 29Meningioma 5Gastro-enteropancreatic neuroendocrine tumor 5Paraganglioma 4Carcinoma, Neuroendocrine 4Pheochromocytoma 3Neuroblastoma 3Neoplasms, Germ Cell and Embryonal 2Neoplasms 2Medulloblastoma 2Glioma 2Ependymoma 2Carcinoma, Merkel Cell 2Carcinoma, Medullary 2Carcinoid Tumor 2Adenoma, Islet Cell 2Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1

Interventions

Parathyroidectomy 5lutetium Lu 177 dotatate 1fluorocholine 1acetaminophen, codeine drug combination 1Tramadol 1Tablets 1Standard of Care 1Sodium Chloride 1Rubidium-82 1Nivolumab 1Magnetic Resonance Spectroscopy 1Denosumab 1Dacarbazine 1Control Groups 1Congresses as Topic 1Cinacalcet 1Capsules 1Bortezomib 1Blood Specimen Collection 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Parathyroid Neoplasms × lutetium Lu 177 dotatate × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡